The nurse is assessing a patient with a burn injury using the "rule of nines." Which information will this assessment contribute to future care planning?

A. Alteplase: Alteplase is a thrombolytic used to dissolve existing clots in conditions such as acute myocardial infarction, ischemic stroke, or massive pulmonary embolism. It is not used routinely for DVT prophylaxis because it carries a high risk of bleeding and is not preventive.

B. Clopidogrel: Clopidogrel is an antiplatelet agent used primarily for arterial thrombotic conditions, such as prevention of stroke or myocardial infarction. It does not provide adequate prophylaxis against venous thromboembolism, which is more platelet-independent and coagulation-factor dependent.

C. Warfarin: Warfarin is an oral anticoagulant that inhibits vitamin K–dependent clotting factors. While it can prevent DVT, it is not typically used immediately postoperatively due to delayed onset of action and the need for close INR monitoring.

D. Enoxaparin: Enoxaparin is a low-molecular-weight heparin commonly prescribed postoperatively to prevent DVT, especially after orthopedic surgeries like total knee replacement. It acts quickly, inhibits factor Xa, and effectively reduces venous thromboembolism risk in high-risk surgical patients.

A. Continue heparin therapy and monitor platelet counts: Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse reaction in which antibodies form against the heparin–platelet factor 4 complex, leading to platelet activation and thrombosis. Continuing heparin can worsen platelet consumption and increase the risk of life-threatening thromboembolic events.

B. Discontinue heparin immediately and start an alternative anticoagulant: The priority intervention in suspected HIT is the immediate cessation of all heparin products to prevent further antibody-mediated platelet activation. Because HIT creates a prothrombotic state, an alternative non-heparin anticoagulant is initiated to reduce the risk of DVT or PE.

C. Administer platelet transfusion to manage thrombocytopenia: In HIT, thrombocytopenia results from platelet activation and consumption, not from decreased production. Transfusing platelets may exacerbate thrombosis by providing additional substrate for clot formation. Platelet transfusions are generally avoided unless there is significant active bleeding.

D. Administer intravenous fluids to prevent dehydration: While maintaining adequate hydration is important for overall circulatory stability, IV fluids do not address the immune-mediated platelet activation or thrombotic risk associated with HIT. The immediate threat is thrombosis, which requires stopping heparin and initiating alternative anticoagulation.